[HTML] springer.com

[HTML][HTML] Evolving strategies in the treatment of anaemia in chronic kidney disease: the HIF-prolyl hydroxylase inhibitors

F Locatelli, R Minutolo, L De Nicola, L Del Vecchio - Drugs, 2022 - Springer
Chronic kidney disease (CKD) affects approximately 10% of the worldwide population;
anaemia is a frequent complication. Inadequate erythropoietin production and absolute or …
被引用次数：24 相关文章
[HTML] nih.gov

[HTML][HTML] Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors

F Locatelli, R Minutolo, L De Nicola, L Del Vecchio - Drugs, 2022 - ncbi.nlm.nih.gov
Chronic kidney disease (CKD) affects approximately 10% of the worldwide population;
anaemia is a frequent complication. Inadequate erythropoietin production and absolute or …

Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF‑Prolyl Hydroxylase Inhibitors

F Locatelli, R Minutolo, L De Nicola, L Del Vecchio - Drugs, 2022 - search.proquest.com
Chronic kidney disease (CKD) affects approximately 10% of the worldwide population;
anaemia is a frequent complication. Inadequate erythropoietin production and absolute or …

Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors

F Locatelli, R Minutolo, L De Nicola, L Del Vecchio - DRUGS, 2022 - iris.unicampania.it
Chronic kidney disease (CKD) affects approximately 10% of the worldwide population;
anaemia is a frequent complication. Inadequate erythropoietin production and absolute or …

Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors

F Locatelli, R Minutolo, L De Nicola… - Drugs, 2022 - pubmed.ncbi.nlm.nih.gov
Chronic kidney disease (CKD) affects approximately 10% of the worldwide population;
anaemia is a frequent complication. Inadequate erythropoietin production and absolute or …

Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors.

F Locatelli, R Minutolo, L De Nicola, L Del Vecchio - Drugs, 2022 - europepmc.org
Chronic kidney disease (CKD) affects approximately 10% of the worldwide population;
anaemia is a frequent complication. Inadequate erythropoietin production and absolute or …

Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors.

F Locatelli, R Minutolo, L De Nicola, L Del Vecchio - Drugs, 2022 - search.ebscohost.com
Chronic kidney disease (CKD) affects approximately 10% of the worldwide population;
anaemia is a frequent complication. Inadequate erythropoietin production and absolute or …

Evolving strategies in the treatment of anaemia in chronic kidney disease: the HIF-prolyl hydroxylase inhibitors.

F Locatelli, R Minutolo, L de Nicola, L del Vecchio - 2022 - cabidigitallibrary.org
Chronic kidney disease (CKD) affects approximately 10% of the worldwide population;
anaemia is a frequent complication. Inadequate erythropoietin production and absolute or …